Drug Price Competition and Patent Term Restoration

Drug price competition and patent term restoration act of 1984, Public 98-417, 98 Stat. 1585-1605, Sept. 24, 1984. 

Drug metabolite production, microbial biotransformations for, 16 398-399 Drug Price Competition and Patent Term Restoration, 15 686 Drug products... 

Fines Enhancement Laws of 1984 and 1987 increase penalties for all federal crimes, with double fines for corporations. The Drug Price Competition and Patent Term Restoration Act expedites the availability of less-costly generic drugs by permitting FDA to approve generics without repeating the safety and effectiveness research. 

The Drug Price Competition and Patent Term Restoration Act of 1984... 

As indicated above, the status of generic versions of both pre-1962 and post-1962 new drugs was settled by Congress in the Drug Price Competition and Patent Term Restoration Act of 1984. That statute will be discussed in greater detail below. 

The vast bulk of prescription drugs on the market today are subject to the requirement for some form of an approved NDA. Following enactment of the Drug Price Competition and Patent Term Restoration Act of 1984, there are now three clearly established types of NDA a full NDA, a paper NDA [now called a Section 505(b)(2) NDA, after the provision in the FD C Act that created it], and an abbreviated NDA. Each of these is discussed in the sections that follow. 

The ffatch-Waxman Act, or the Drug Price Competition and Patent Term Restoration Act, makes it easier for generic drugs to get approval from the FDA but also allows drug companies to extend their patents when the FDA approval process delays the sales of patented drugs. 

The pharmaceutical marketplace has also become more crowded as innovative pharmaceutical firms compete with a growing number of generic producers as well as their own products via parallel importation. The passage of the 1984 Drug Price Competition and Patent Term Restoration Act (The Hatch-Waxman Act) intensified... 

Passage of the 1984 Drug Price Competition and Patent Term Restoration Act (Waxman-HatchAct) permits the FDA to use an expedited review process for approval of generic versions of brand-name drugs that have been found to be safe and effective but are no longer protected by a patent.The expedited review process is known as an abbreviated new drug application (ANDA). 

---